4-Methylumbeliferone Treatment at a Dose of 1.2 g/kg/Day Is Safe for Long-Term Usage in Rats

4-methylumbelliferone (4MU) has been suggested as a potential therapeutic agent for a wide range of neurological diseases. The current study aimed to evaluate the physiological changes and potential side effects after 10 weeks of 4MU treatment at a dose of 1.2 g/kg/day in healthy rats, and after 2 months of a wash-out period. Our findings revealed downregulation of hyaluronan (HA) and chondroitin sulphate proteoglycans throughout the body, significantly increased bile acids in blood samples in weeks 4 and 7 of the 4MU treatment, as well as increased blood sugars and proteins a few weeks after 4MU administration, and significantly increased interleukins IL10, IL12p70 and IFN gamma after 10 weeks of 4MU treatment. These effects, however, were reversed and no significant difference was observed between control treated and 4MU-treated animals after a 9-week wash-out period

Pathological Alterations in Hepatocytes of Dairy Cows With a Tendency to Emaciation and Fattening

The aim of this study was to demonstrate the histochemical and histopathological alterations in the livers of cows with a tendency to become emaciated (body condition score - BCS1 and 2) and a tendency to become fattened (BCS4 and 5) in comparison to the cows of average body condition (BCS3) presented as a control. The histochemical analysis (PAS reaction) showed that the influence of emaciation and fattening in our study was manifested by a decreased occurrence of glycogen and a decreased level of the PAS-positive matter in the hepatocytes of dairy cows with BCS1, 2, 4 and 5. An abundant accumulation of lipids in the form of large lipid droplets, liposomes and lipoproteins observed in the hepatocytes of emaciated and fattened (BCS1 and 5) cows may be related to moderate-severe steatosis. These observations suggest a relationship between liver steatosis and the occurrence of lipoproteins in cows with a tendency toward emaciation and fattening